Related references
Note: Only part of the references are listed.Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
William Kevin Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Abstract A233: Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone.
F. Schimmoller et al.
MOLECULAR CANCER THERAPEUTICS (2012)
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
Weon-Kyoo You et al.
CANCER RESEARCH (2011)
MET and VEGF: synergistic targets in castration-resistant prostate cancer
Dana T. Aftab et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2011)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Steroidogenic Enzymes and Stem Cell Markers Are Upregulated during Androgen Deprivation in Prostate Cancer
Minja J. Pfeiffer et al.
MOLECULAR MEDICINE (2011)
Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
Alison H. M. Reid et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells
Shumin Zhang et al.
MOLECULAR CANCER (2010)
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
Evan Y. Yu et al.
CLINICAL CANCER RESEARCH (2009)
Vascular endothelial growth factor regulates osteoblast survival – evidence for an autocrine feedback mechanism
John Street et al.
Journal of Orthopaedic Surgery and Research (2009)
A phase II clinical trial of sorafenib in androgen-independent prostate cancer
William L. Dahut et al.
CLINICAL CANCER RESEARCH (2008)
The androgen receptor negatively regulates the expression of c-Met: Implications for a novel mechanism of prostate cancer progression
Meletios Verras et al.
CANCER RESEARCH (2007)
Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line, BALB/c-MC
Katsuhiro Ono et al.
BONE (2006)
Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 150005/9480
Peter A. Humphrey et al.
CLINICAL GENITOURINARY CANCER (2006)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Microarray analysis of progression to reduced prostate cancer androgen dependence: Studies in unique models contrasts early and late molecular events
FM Sirotnak et al.
MOLECULAR CARCINOGENESIS (2004)
High expression of the Met receptor in prostate cancer metastasis to bone
BS Knudsen et al.
UROLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
